Biotech Market 2024. As we step into 2024, the biotech industry is a hub of opportunities that promise transformative breakthroughs. The approval of the first crispr gene therapy, casgevy, in december 2023 opens the doors.
The total value of biotech m&a in 2023 stood at $122.2 billion, up 45% from $84.2 billion a year earlier. A run of offerings in the first six weeks of 2024, most worth around $100 million or more, has put the sector on its strongest pace since 2021.
Is This The New Normal For Ipos?
Discover trends shaping the landscape ahead.
This 33Rd Edition Of Our Beyond Borders Report Sees The Us And European Biotechnology (Biotech) Industry Seeking A New Path Forward.
Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.
A Report By Pwc Suggests That Dealmaking Is Expected To.
Images References :
Deal Volume Should Remain Strong In 2024 As Large Pharma Concerns Have Large Cash Balances, Face Key Patent Expirations And Desire Entry Into New Markets.
Sponsored by icon feb 26, 2024 8:00am.
The Approval Of The First Crispr Gene Therapy, Casgevy, In December 2023 Opens The Doors.
The first quarter of 2024 witnessed a surge in initial public offerings (ipos) and mergers and acquisitions (m&a).
Last Year Brought A Stock Market Slide And Layoffs For More Than 150 Drug.